Page last updated: 2024-11-03

proadifen and Carcinoma, Ovarian Epithelial

proadifen has been researched along with Carcinoma, Ovarian Epithelial in 1 studies

Proadifen: An inhibitor of drug metabolism and CYTOCHROME P-450 ENZYME SYSTEM activity.

Carcinoma, Ovarian Epithelial: A malignant neoplasm that originates in cells on the surface EPITHELIUM of the ovary and is the most common form of ovarian cancer. There are five histologic subtypes: papillary serous, endometrioid, mucinous, clear cell, and transitional cell. Mutations in BRCA1, OPCML, PRKN, PIK3CA, AKT1, CTNNB1, RRAS2, and CDH1 genes are associated with this cancer.

Research Excerpts

ExcerptRelevanceReference
"Proadifen (SKF-525A) is a P450 monooxygenase inhibitor with potential anti-proliferative activity and the ability to potentiate the toxicity of hypericin-mediated photodynamic therapy and mitoxantrone via alteration of ABC transport proteins."1.43Proadifen sensitizes resistant ovarian adenocarcinoma cells to cisplatin. ( Fedoročko, P; Hiľovská, L; Jendželovská, Z; Jendželovský, R; Kovaľ, J; Mikeš, J, 2016)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Jendželovský, R1
Jendželovská, Z1
Hiľovská, L1
Kovaľ, J1
Mikeš, J1
Fedoročko, P1

Other Studies

1 other study available for proadifen and Carcinoma, Ovarian Epithelial

ArticleYear
Proadifen sensitizes resistant ovarian adenocarcinoma cells to cisplatin.
    Toxicology letters, 2016, Jan-22, Volume: 243

    Topics: Apoptosis; bcl-2-Associated X Protein; bcl-X Protein; Carcinoma, Ovarian Epithelial; Cell Line, Tumo

2016